The Claim
Bempedoic acid is not associated with an increased risk of muscle-related adverse events in statin-intolerant patients, with observed incidence rates of 5.6% for bempedoic acid and 6.8% for placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients who cannot tolerate statins, bempedoic acid does not cause more muscle-related side effects than a placebo, with 5.6% of users experiencing such events compared to 6.8% in the placebo group.
See the scientific wording
Bempedoic acid does not increase the risk of muscle-related adverse events in statin-intolerant patients, with incidence rates of 5.6% compared to 6.8% in placebo, supporting its use as a non-muscle-toxic alternative to statins.
Bempedoic acid works only in the liver to block a key step in cholesterol production, which lowers bad cholesterol in the blood. It does not activate in muscle tissue, so it does not interfere with muscle energy processes or cause muscle damage.
What the research says
1 studyStudy: Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
This medicine, bempedoic acid, was tested in people who can't take statins because of muscle pain, and it didn't cause more muscle problems than a sugar pill — so it's a safe alternative for them.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.